Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wadsworth

Showing results (91-100 of 96) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 96 results.
Annals of the New York Academy of Sciences|June 30, 1983
Mucosal immunityL A Hanson, S Ahlstedt, B Andersson, et al.
Lancet (London, England)|May 21, 2017
Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trialJeffrey S Heier, Saleema Kherani, Shilpa Desai, et al.
Journal of Virology|December 1, 1996
Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrenceK M Hehir, D Armentano, L M Cardoza, et al.
Chemistryopen|March 1, 2024
Computational Design of Phosphotriesterase Improves V-Agent Degradation EfficiencyJacob Kronenberg, Stanley Chu, Andrew Olsen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 5, 2004
AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry miceRobin J Ziegler, Scott M Lonning, Donna Armentano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2020
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trialL Paz-Ares, A Spira, D Raben, et al.
Pageof 10

Showing results (91-100 of 96) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 96 results.
Annals of the New York Academy of Sciences|June 30, 1983
Mucosal immunityL A Hanson, S Ahlstedt, B Andersson, et al.
Lancet (London, England)|May 21, 2017
Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trialJeffrey S Heier, Saleema Kherani, Shilpa Desai, et al.
Journal of Virology|December 1, 1996
Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrenceK M Hehir, D Armentano, L M Cardoza, et al.
Chemistryopen|March 1, 2024
Computational Design of Phosphotriesterase Improves V-Agent Degradation EfficiencyJacob Kronenberg, Stanley Chu, Andrew Olsen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 5, 2004
AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry miceRobin J Ziegler, Scott M Lonning, Donna Armentano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2020
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trialL Paz-Ares, A Spira, D Raben, et al.
Pageof 10